Study of Montelukast for the Treatment of Respiratory Symptoms of Post–Respiratory Syncytial Virus Bronchiolitis in Children

Bisgaard, Hans; A, Flores-Núñez; Goh, Anne; Azimi, Parvin H.; Halkas, Andrew; Malice, Marie‐Pierre; Marchal, Jean-Louis; Dass, Sairia; Reiss, Theodore F.; Knorr, Barbara

doi:10.1164/rccm.200706-910oc

Cited by 135 publications

(122 citation statements)

References 23 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…In one of the few double-blind, placebo-controlled, parallel-group multicenter studies on children with seasonal allergen sensitivity, montelukast over a 3-week treatment during the allergy season didn't significantly improve FEV 1 [79]. Taking into account the modest effects, as well as the negative results on the natural history of wheeze [80], the chances for montelukast to prevent the development of asthma in children with AR, although not evaluated, appear not very high.…”

Section: Pharmacotherapymentioning

confidence: 97%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

Section: Pharmacotherapymentioning

confidence: 97%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Este aumento que encontramos en nuestra población también viene reflejado en los datos de consumo del Sistema Nacional de Salud (SNS) extraído de los boletines de Información Terapéuti-ca del SNS, donde se detallan los subgrupos ATC (sistema de clasificación anatómica, terapéutica, química) de mayor consumo a nivel nacional, siendo el gasto nacional correspondiente al grupo de antileucotrienos de 79,9 millones de € en 2006 (1.833,3 miles de envases) (19) Originales está indicado. El uso de montelukast para indicaciones no aprobadas en ficha técnica no se considera adecuado ni siquiera como uso compasivo, ya que no hay evidencias suficientes de la eficacia del montelukast en estos procesos (24)(25)(26).…”

Section: Discussionunclassified

Calidad de prescripción de montelukast en pacientes adultos: Estudio en tres farmacias comunitarias de la Comunidad Valenciana

Molina

Navaza

et al. 2014

View full text Add to dashboard Cite

RESUMENIntroducción: El objetivo de este trabajo es analizar la utilización de montelukast en adultos desde tres farmacias comunitarias.Material y métodos: Estudio descriptivo, observacional en tres farmacias comunitarias (enero 2009 -febrero 2013) en pacientes mayores de 15 años que acuden a la farmacia con receta de montelukast. Los datos se recogen a través de encuesta (edad, patología, régimen terapéutico, duración del tratamiento, medicación asociada) y se valora la idoneidad de la prescripción según las indicaciones autorizadas y su adecuación a las guías de práctica clínica. Se remitió al médico, cuando se detectó un tratamiento inadecuado para la revisión del mismo.Resultados: Se incluyen un total de 106 pacientes, de los cuales, el 26 % no padece asma y están tomando montelukast fuera de indicación. De los asmáticos, el 29 % de los tratamientos pautados no se ajusta a las recomendaciones de las guías. Destaca tanto la elevada instauración de montelukast como tratamiento de inicio (59 % asmáticos, 63 % no asmáticos), como el empleo de montelukast en monoterapia (16 % asmáticos, 41 % no asmáticos).Conclusiones: Se está haciendo un uso fuera de indicación de montelukast en pacientes no asmáticos con rinitis alérgica o bronquitis que podría derivar de la falta de claridad en las indicaciones de algunas guías. Además, en pacientes asmáticos, no siempre se está utilizando montelukast según las recomendaciones de las guías clínicas, lo que evidencia la necesidad de información clara a los profesionales sanitarios sobre el papel de montelukast en la terapéutica actual. The Quality of Montelukast Prescriptions in Adult Patients. A Study in three Community Pharmacies in the Valencia Region ABSTRACTIntroduction: The objective of this piece of work is to analyse the use of Montelukast in adults from three community pharmacies.Material and Methods: Descriptive, observational study in three community pharmacies (January 2009 -February 2013, in patients over the age of 15 who went to the pharmacy with a prescription for Montelukast. Their data was collected in a questionnaire (age, pathology, therapeutic regime, duration of the treatment, associated medication) and the suitability of the prescription was assessed according to the authorised indications and their adaptation to clinical practice guides. The patient was sent to the doctor when inadequate treatment was detected, to have it reviewed.Results: 106 patients were included, of whom 26 % did not suffer from asthma and were taking Montelukast inappropriately. Of the asthmatics, 29 % of the treatments prescribed did not adapt to the recommendations given in the guides. We would highlight the high level of establishment of Montelukast as an initial treatment (59 % asthmatics, 63 % non-asthmatics), as well as the use of Montelukast in single-drug therapy (16 % asthmatics, 41 % non-asthmatics).Conclusions: Montelukast is being used incorrectly in non-asthmatic patients with allergic rhinitis or bronchitis which could lead to a lack of clarity in the indications in so...

show abstract

“…Unfortunately, results from 3 prospective randomized, double-blind, placebo-controlled follow-on trials in children less than 24 months of age were not consistent, leaving a potential benefit of montelukast treatment on post-RSV bronchiolitis symptoms unclear. A first study in 979 patients randomized to placebo or to montelukast treatment at 4 or 8 mg/day for 4 or 20 weeks did not show a significant difference in the percentage of symptom-free days (SFD) over a treatment period of 4 weeks (Bisgaard et al, 2008). In both groups, % SFD was approximately 29%.…”

Section: Anti-inflammatory Agentsmentioning

confidence: 99%